LIMN
Liminatus Pharma, Inc. Class A Common Stock
NASDAQ · Healthcare · Biotechnology · US
$3.71
+0.27%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.3x
Market Cap
$4.98M
MomentumView details →
1D Return
+0.27%
YTD Return
+500.00%
RSI (14)
68.9
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.3x
Market Cap
$4.98M
RSI (14)
68.9
MomentumView details →
1D Return
+0.27%
YTD Return
+500.00%
SummaryUpdated Jun 1, 2026
Liminatus Pharma, Inc. (NASDAQ:LIMN) is a clinical-stage biotechnology company founded and based in La Palma, California. The company went public in May 2025, representing a relatively new entrant to the public markets in the immuno-oncology space. As a clinical-stage company, Liminatus is focused on developing novel cancer therapies that harness the body's immune system to fight cancer, though the company is still in early stages of development with no current revenue generation.
Similar companies
Latest newsMore news →
Liminatus Pharma, Inc. announced a 1-for-50 reverse stock split of its common stock, approved by its board and stockholders at the 2026 Annual Meeting held on August 3, 2026.17d agoLiminatus Pharma, Inc. received a notice from NASDAQ on 2026-08-12 that it is not in compliance with Listing Rule 5550(a)(2) regarding minimum bid price, and plans to implement a 1-for-50 reverse stock split.18d agoLiminatus Pharma, Inc. issued 11,188,729 shares of common stock and 158,881.1271 shares of newly designated Series A Non-Voting Convertible Preferred Stock in connection with its merger, exempt from registration under Section 4(a)(2) of the Securities Act of 1933.61d ago